Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Frequency Therapeutics, Inc.

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics to Present at Upcoming Investor Conferences
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America’s Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
From Frequency Therapeutics, Inc.
Via Business Wire
Tickers FREQ
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.